|
Market Closed -
Nasdaq
07:00:00 07/10/25 am AEDT
|
5-day change | 1st Jan Change | ||
| 5.670 USD | -.--% |
|
-.--% | - |
| 08/10/25 | MannKind Corporation completed the acquisition of scPharmaceuticals Inc.. | CI |
| 08/10/25 | MannKind Completes Acquisition of scPharmaceuticals | MT |
| Market Cap | 305M 269M 255M 231M 433M 29.25B 437M 3.05B 1.18B 14.94B 1.14B 1.12B 48.07B | P/E 2023 |
-4.41x | P/E 2024 | -1.85x |
|---|---|---|---|---|---|
| Enterprise Value | 281M 248M 235M 213M 399M 26.95B 403M 2.81B 1.08B 13.76B 1.05B 1.03B 44.28B | EV / Sales 2023 |
13,839,720x | EV / Sales 2024 | 4,215,542x |
| Free-Float |
98.42% | Yield 2023 * |
-
| Yield 2024 | - |
| 1 year | 5.64 |  | 5.7 |
| 3 years | 1.94 | | 7.1 |
| 5 years | 1.94 | | 12.75 |
| 10 years | 1.94 | | 18.17 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Castagna
CEO | Chief Executive Officer | 49 | 07/10/2025 |
| Director of Finance/CFO | 50 | 07/10/2025 | |
David Thomson
SEC | Corporate Secretary | 59 | 07/10/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Michael Castagna
BRD | Director/Board Member | 49 | 07/10/2025 |
David Thomson
BRD | Director/Board Member | 59 | 07/10/2025 |
| Director/Board Member | 50 | 07/10/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 7/10/25 | Tender | Chairman | 77,174 | 0.1542% | ||
| 7/10/25 | Tender | Director | 177,950 | 0.3556% | ||
| 7/10/25 | Issuer sale | Director | 72,174 | 0.1442% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | -.--% | -20.37% | 305M | |
| -0.01% | +1.24% | +63.06% | +120.55% | 1,056B | |
| -1.61% | -0.60% | +47.32% | +71.79% | 655B | |
| -1.12% | -0.72% | +17.98% | +76.63% | 471B | |
| -1.72% | -4.06% | +36.39% | +39.47% | 342B | |
| -0.40% | +3.83% | +22.08% | +28.82% | 277B | |
| -0.51% | -1.05% | +12.98% | +12.92% | 257B | |
| +1.32% | +3.27% | +54.63% | +57.63% | 226B | |
| -0.61% | -0.91% | +34.33% | +101.87% | 189B | |
| -0.24% | -3.21% | -27.79% | -61.37% | 170B | |
| Average | -0.17% | +0.87% | +26.10% | +42.79% | 364.32B | |
| Weighted average by Cap. | -0.05% | +1.04% | +39.00% | +70.56% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 13.59 12 11.35 10.29 19.3 1.3K 19.49 136.16 52.48 666.05 51.04 49.93 2.14K | 36.33 32.06 30.34 27.51 51.58 3.49K 52.09 363.93 140.26 1.78K 136.43 133.46 5.73K |
| Net income | -54.81M -48.37M -45.77M -41.5M -77.81M -5.26B -78.58M -549M -212M -2.69B -206M -201M -8.64B | -85.15M -75.14M -71.1M -64.48M -121M -8.17B -122M -853M -329M -4.17B -320M -313M -13.43B |
| Net Debt | -36.72M -32.41M -30.66M -27.81M -52.13M -3.52B -52.65M -368M -142M -1.8B -138M -135M -5.79B | -23.98M -21.16M -20.03M -18.16M -34.05M -2.3B -34.38M -240M -92.59M -1.18B -90.06M -88.1M -3.78B |
Employees
163
Sector
Pharmaceuticals
- Stock Market
- Stocks
- SCPH Stock
Select your edition
All financial news and data tailored to specific country editions
